ABSTRACT Objective Prognostication of disease course and prediction of treatment response in multiple sclerosis is an unmet need. We compared the performance of serum neurofilament light chain Z scores (age‐ and BMI‐adjusted) with absolute concentrations for the prediction of response to disease‐modifying therapy.
Maximilian Einsiedler+43 more
wiley +1 more source
Delivering Telemedical Services to Children with Special Health Care Needs: Patient and Provider Characteristics and Perceptions † 646 [PDF]
William P. Kanto+7 more
openalex +1 more source
ZotCare: a flexible, personalizable, and affordable mhealth service provider. [PDF]
Labbaf S+4 more
europepmc +1 more source
Cytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis
ABSTRACT Objectives To investigate the value of cytokine, chemokine, and neurofilament light chain (NfL) concentrations in predicting relapse risk, chronic epilepsy, and functional impairment in LGI1 autoimmune encephalitis (AE). Methods Cytokines/chemokines (IL‐1‐beta, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8/CXCL8, IL‐10, IL‐12p70, IL‐13, IL‐17A, GM‐CSF, TNF ...
Albert Aboseif+17 more
wiley +1 more source
Book Review: Optimizing Genetics Services in a Social, Ethical, and Policy Context-Suggestions from Consumers and Providers in the New England Regional Genetics Group (NERGG). By Dorothy C. Wertz and Robin Gregg. The Genetic Resource, Volume 10, Number 2, [PDF]
Debra Lochner Doyle
openalex +1 more source
Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons
ABSTRACT Objectives This ongoing, open‐label extension study is evaluating the long‐term safety, tolerability, and efficacy of givinostat, a Class I and II histone deacetylase inhibitor, in patients with Duchenne muscular dystrophy (DMD). Methods The recruited patients completed one of two prior clinical studies (one Phase 2 and one Phase 3 [EPIDYS ...
Craig M. McDonald+74 more
wiley +1 more source
Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin+10 more
wiley +1 more source
Provider-Related Predictors of Utilization of University Health Services in Nigeria
Olumide Abiodun+2 more
openalex +2 more sources
Collaboration Among Community Members, Local Health Service Providers, and Researchers in an Urban Research Center in Harlem, New York [PDF]
Sandro Galea+6 more
openalex +3 more sources
Custom Synthesis as a Full-Service Program
In recent years, the requirements of the pharmaceutical industry with respect to their outsourcing partners increased and changed quite drastically.
Franziska Gnehm
doaj